Where Your News Is Made.
Reach your press release and disclosure targets.
Get more views with multimedia.
Track your results and refine your message.
Be the news everyone talks about.
Latest News
Today is September 22, 2018.
All times in Eastern Daylight Time.
-
European Medicines Agency Validates Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Multiple Myeloma
PRINCETON, N.J.--(BUSINESS WIRE)--European Medicines Agency Validates BMS’s Application for Empliciti Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Multiple Myeloma more » -
Bristol-Myers Squibb Announces Dividend
NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend more » -
Bristol-Myers Squibb’s Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis in Phase 2 Trial
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb’s Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis more » -
Bristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference more » -
Bristol-Myers Squibb to Announce Results for Third Quarter 2018 on October 25
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb to Announce Results for Third Quarter 2018 on October 25 more » -
Bristol-Myers Squibb Kicks Off Coast 2 Coast 4 Cancer Ride to Fundraise for the V Foundation for Cancer Research
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Kicks Off Coast 2 Coast 4 Cancer Ride to Fundraise for the V Foundation for Cancer Research more » -
U.S. Food and Drug Administration Accepts Bristol-Myers Squibb’s Application for Sprycel (dasatinib) in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
PRINCETON, N.J.--(BUSINESS WIRE)--US FDA Accepts BMS's Application for Sprycel in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia more » -
Bristol-Myers Squibb Appoints Christopher Boerner Executive Vice President and Chief Commercial Officer
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Appoints Christopher Boerner Executive Vice President and Chief Commercial Officer more » -
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J.--(BUSINESS WIRE)--U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) more »